1. Home
  2. LQDA vs NATL Comparison

LQDA vs NATL Comparison

Compare LQDA & NATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • NATL
  • Stock Information
  • Founded
  • LQDA 2004
  • NATL 2023
  • Country
  • LQDA United States
  • NATL United States
  • Employees
  • LQDA N/A
  • NATL N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • NATL
  • Sector
  • LQDA Health Care
  • NATL
  • Exchange
  • LQDA Nasdaq
  • NATL Nasdaq
  • Market Cap
  • LQDA 2.5B
  • NATL 2.9B
  • IPO Year
  • LQDA 2018
  • NATL N/A
  • Fundamental
  • Price
  • LQDA $25.00
  • NATL $39.30
  • Analyst Decision
  • LQDA Strong Buy
  • NATL Buy
  • Analyst Count
  • LQDA 9
  • NATL 4
  • Target Price
  • LQDA $32.11
  • NATL $42.75
  • AVG Volume (30 Days)
  • LQDA 2.2M
  • NATL 651.4K
  • Earning Date
  • LQDA 11-12-2025
  • NATL 11-11-2025
  • Dividend Yield
  • LQDA N/A
  • NATL N/A
  • EPS Growth
  • LQDA N/A
  • NATL N/A
  • EPS
  • LQDA N/A
  • NATL 1.71
  • Revenue
  • LQDA $19,322,000.00
  • NATL $4,271,000,000.00
  • Revenue This Year
  • LQDA $405.58
  • NATL $2.73
  • Revenue Next Year
  • LQDA $373.93
  • NATL $4.51
  • P/E Ratio
  • LQDA N/A
  • NATL $23.04
  • Revenue Growth
  • LQDA 30.20
  • NATL N/A
  • 52 Week Low
  • LQDA $9.68
  • NATL $22.30
  • 52 Week High
  • LQDA $29.94
  • NATL $40.78
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 45.82
  • NATL 58.96
  • Support Level
  • LQDA $25.34
  • NATL $38.43
  • Resistance Level
  • LQDA $28.00
  • NATL $40.47
  • Average True Range (ATR)
  • LQDA 1.32
  • NATL 1.01
  • MACD
  • LQDA -0.70
  • NATL -0.36
  • Stochastic Oscillator
  • LQDA 0.50
  • NATL 52.26

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About NATL NCR Atleos Corporation

NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.

Share on Social Networks: